Entropy Technologies LP Takes Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Entropy Technologies LP purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,960 shares of the company's stock, valued at approximately $445,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wolverine Asset Management LLC bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth $27,000. True Wealth Design LLC bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth $27,000. Capital Performance Advisors LLP bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth $56,000. KBC Group NV grew its stake in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company's stock worth $76,000 after purchasing an additional 679 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company's stock worth $130,000 after purchasing an additional 781 shares in the last quarter. Institutional investors own 96.29% of the company's stock.

Insider Buying and Selling

In other news, insider Caroline Baumal sold 2,816 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the sale, the insider now directly owns 55,560 shares of the company's stock, valued at $1,878,483.60. This trade represents a 4.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the firm's stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $33,351.28. Following the sale, the chief accounting officer now directly owns 48,138 shares of the company's stock, valued at $1,464,839.34. This trade represents a 2.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,365 shares of company stock valued at $1,810,479. Corporate insiders own 6.80% of the company's stock.

Apellis Pharmaceuticals Stock Down 0.2 %

Apellis Pharmaceuticals stock traded down $0.06 during mid-day trading on Friday, hitting $27.40. The company's stock had a trading volume of 1,287,866 shares, compared to its average volume of 1,715,733. The firm's 50 day moving average is $31.21 and its 200 day moving average is $32.09. The company has a market cap of $3.41 billion, a PE ratio of -13.50 and a beta of 0.96. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $71.90.

Analysts Set New Price Targets

APLS has been the subject of several research reports. Robert W. Baird decreased their target price on Apellis Pharmaceuticals from $92.00 to $55.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. Bank of America decreased their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. HC Wainwright reaffirmed a "buy" rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Thursday. The Goldman Sachs Group cut Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and set a $36.00 target price for the company. in a research note on Tuesday, December 17th. Finally, Oppenheimer decreased their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.71.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).